Valuation
- Market cap
- 103,343,000
- Revenue TTM
- $71,230,000
- Net income TTM
- $-51,930,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -72.90%
- Debt to equity
- -1.90
Trading
- Volume
- 7,100
- Avg volume
- —
- Day's range
- $0.15 – $0.15
- Shares out
- 688,953,000
- Stochastic %K
- —
- Beta
- 0.85
- Analysts
- —
- Price target
- —
Company profile
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics prod...
Show more
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen; and VLP Peanut, a short-course peanut allergy vaccine. Allergy Therapeutics plc was founded in 1998 and is headquartered in Worthing, the United Kingdom.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Phone
- 44 1903 844 700
- Website
- https://www.allergytherapeutics.com
- Address
- Dominion Way, Worthing, United Kingdom
Latest news
No headlines yet.
